smp-100
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04296799)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 3a (5-HT3a) receptorPARTIAL AGONIST
HTR3A partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05029518 | Phase 1 | Sep 9, 2021 | CMAX Clinical Research, Xiling Lab |
| NCT04296799 | Phase 1 | May 31, 2020 | CMAX Clinical Research, Xiling Lab |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CMAX Clinical Research | For profit | 2 | 0 | 1 | 2020 |
| Xiling Lab | For profit | 2 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1